Walladbegi, Java http://orcid.org/0000-0001-5660-1348
Henriksson, Roger
Tavelin, Björn
Svanberg, Anncarin http://orcid.org/0000-0003-2960-4994
Larfors, Gunnar
Jädersten, Martin
Schjesvold, Fredrik
Mahdi, Aram
Garming Legert, Karin http://orcid.org/0000-0001-8276-0510
Peterson, Douglas E. http://orcid.org/0000-0002-2665-4964
Jontell, Mats http://orcid.org/0000-0003-3753-7314
Funding for this research was provided by:
VINNOVA (2016-04171)
BrainCool AB
Article History
Received: 14 July 2021
Revised: 15 October 2021
Accepted: 19 October 2021
First Online: 3 November 2021
Competing interests
: BT, GL, KGL, and M Jädersten have no conflicts of interest to disclose. JW, AS, AM, and DEP report personal fees from BrainCool AB. RH reports personal fees from BrainCool AB, The National Swedish Beneficiary Authority (Government), and from EMA (European Medical Agency). FS reports personal fees from Amgen, Takeda, Skylite DX, and from Novartis, grants and personal fees from Celgene/BMS, Janssen, Oncopeptides and Sanofi, and grants from GSK. M Jontell reports consultation fee from Braincool AB and grants from Braincool AB.